Search results
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
How does Emend work? Aprepitant, the active substance in Emend, is a neurokinin 1 (NK1) receptor antagonist. It prevents a chemical in the body (substance P) from attaching to the NK1 receptors. When substance P attaches to these receptors, it causes nausea and vomiting. By blocking the receptors, Emend can prevent nausea
Introduction. Emend is an oral substance P, aka human neurokinin 1 (NK-1)-receptor antagonist. Mammalian tachykinin substance P (SP) that binds to the NK-1 receptor has been associated with numerous inflammatory conditions, mediation of the emetic reflex and modulation of central nervous system disorders.
Co zawiera i jak działa Emend - kapsułki twarde? Zapobieganie nudnościom i wymiotom związanym z chemioterapią przeciwnowotworową o dużym i umiarkowanym ryzyku wymiotów u dorosłych i młodzieży w wieku od 12 lat. Preparat stosuje się w leczeniu skojarzonym.
2 wrz 2015 · EMEND is administered as part of a 3-day regimen for the prevention of nausea and vomiting associated with HEC or MEC in adults and pediatric patients 12 years of age and older and patients less than 12 years of
22 kwi 2024 · Expert Opinion. EMEND® 125 mg powder for oral suspension is the only licensed product containing aprepitant that is appropriate for paediatric patients under age 12. It has been reported that this product is in short supply in several of the member states in which it is licensed.
4 lut 2016 · today announced that the U.S. Food and Drug Administration (FDA) has. approved a supplemental new drug application (sNDA) for single-dose EMEND ®. (fosaprepitant dimeglumine) for injection, Merck’s substance. P/neurokinin-1 (NK 1) receptor antagonist, in combination with.
